3 results on '"Daniele Marinelli"'
Number of results to display per page
Search Results
2. From bench to bedside: Impact of left ventricular assist device outflow conduit anastomosis position on outcome
- Author
-
Silvia Scuri, Assunta Fabozzo, Daniele Marinelli, Chiara Tessari, Gino Gerosa, Vincenzo Tarzia, Ugolino Livi, M. Maiani, Tomaso Bottio, Dario Gregori, Sonia Bernazzali, Gabriele Di Giammarco, Massimo Maccherini, Lorenzo Bagozzi, and Giacomo Bortolussi
- Subjects
Male ,medicine.medical_treatment ,heart failure ,Medicine (miscellaneous) ,02 engineering and technology ,030204 cardiovascular system & hematology ,Postoperative Complications ,0302 clinical medicine ,Hospital Mortality ,Aorta ,Anastomosis, Surgical ,General Medicine ,Middle Aged ,Cardiac surgery ,Treatment Outcome ,Creatinine ,Descending aorta ,cardiovascular system ,Cardiology ,Female ,medicine.medical_specialty ,0206 medical engineering ,Biomedical Engineering ,Bioengineering ,aortic anastomosis ,Anastomosis ,Prosthesis Design ,Hemolysis ,outflow graft ,ventricular assist device ,Prosthesis Implantation ,Biomaterials ,03 medical and health sciences ,medicine.artery ,Internal medicine ,Ascending aorta ,medicine ,Humans ,Aged ,business.industry ,Hemodynamics ,medicine.disease ,020601 biomedical engineering ,Cannula ,Ventricular assist device ,Heart failure ,Heart-Assist Devices ,business - Abstract
Continuous flow left ventricular assist devices (LVADs) have become a valuable therapy for end-stage heart failure. In vitro research highlighted a role of outflow cannula position on the pattern of blood flow in the aorta. However, the clinical effects of the alterations of flow remain unclear. We investigate short- and long-term outcomes of patients implanted with Jarvik 2000 LVAD, according to the ascending (Group 1) versus descending (Group 2) outflow graft connection to the aorta in a multicenter study. From May 2008 to October 2014, 140 consecutive end-stage heart failure patients underwent Jarvik 2000 LVAD implantation in 17 Italian centers. According with a preliminary multivariate analysis, we selected the 90 patients implanted in the four high-volume centers to avoid bias (Group 1 n = 39, Group 2 n = 51). Among the groups, no differences were recorded in the hospital mortality and the main complications occurring after LVAD implantation were similar. In multivariable analysis, the ascending aorta outflow cannula position and higher creatinine at discharge were significant predictors for long-term survival. Postimplant hemolysis was more pronounced in descending aorta outflow graft anastomosis. Outflow graft anastomosis to the ascending aorta is associated with better long-term survival, independent of age and perfusion techniques, reflecting the previous in vitro results.
- Published
- 2020
- Full Text
- View/download PDF
3. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence
- Author
-
Aangela Vaccaro, Antonio Giordano, Marina Elena Cazzaniga, Antonio Russo, Maddalena Barba, Emilio Bria, Corrado Ficorella, Claudio Botti, Nicla La Verde, Clara Natoli, Valentina Magri, Loretta D'Onofrio, Carlo Garufi, Ruggero De Maria, Maria Rosaria Valerio, Gennaro Ciliberto, Mario Roselli, A. Fabbri, Emanuela Magnolfi, Giuseppina Rosaria Rita Ricciardi, Patrizia Vici, Alessandra Cassano, Emanuela Risi, Isabella Sperduti, Daniele Generali, Daniele Marinelli, Vito Lorusso, Teresa Gamucci, Lorenzo Livi, Giuseppe Tonini, Antonino Grassadonia, Editta Baldini, Marco Mazzotta, Luca Moscetti, Silverio Tomao, Claudio Zamagni, Silvia Carpano, Ornella Garrone, Icro Meattini, Giuseppe Sanguineti, Eriseld Krasniqi, Lucia Mentuccia, Katia Cannita, Daniele Santini, Rossana Mirabelli, Enzo Veltri, Domenico Sergi, Aandrea Michelotti, Alice Villa, Nicola Tinari, Vincenzo Adamo, A. Botticelli, Ramy Kayal, Mirco Pistelli, Domenico Corsi, Pietro Del Medico, Rossana Berardi, Enrico Cortesi, Giacomo Barchiesi, Alain Gelibter, Ida Paris, Elisa Landucci, Pia Di Stefano, Laura Pizzuti, Paolo Marchetti, Luisa Carbognin, Francesco Giotta, A.F. Scinto, Krasniqi, E, Pizzuti, L, Barchiesi, G, Sergi, D, Carpano, S, Botti, C, Kayal, R, Sanguineti, G, Marchetti, P, Botticelli, A, Marinelli, D, Gamucci, T, Natoli, C, Grassadonia, A, Tinari, N, Tomao, S, Tonini, G, Santini, D, Michelotti, A, Mentuccia, L, Vaccaro, A, Magnolfi, E, Gelibter, A, Magri, V, Cortesi, E, D'Onofrio, L, Cassano, A, Cazzaniga, M, Moscetti, L, Fabbri, A, Scinto, A, Corsi, D, Carbognin, L, Bria, E, La Verde, N, Garufi, C, Di Stefano, P, Mirabelli, R, Veltri, E, Paris, I, Giotta, F, Lorusso, V, Landucci, E, Ficorella, C, Roselli, M, Adamo, V, Ricciardi, G, Russo, A, Valerio, M, Berardi, R, Pistelli, M, Cannita, K, Zamagni, C, Garrone, O, Baldini, E, Livi, L, Meattini, I, Del Medico, P, Generali, D, De Maria, R, Risi, E, Ciliberto, G, Villa, A, Sperduti, I, Mazzotta, M, Barba, M, Giordano, A, Vici, P, Eriseld K., Laura P., Giacomo B., Domenico S., Silvia C., Claudio B., Ramy K., Giuseppe S., Paolo M., Andrea B., Daniele M., Teresa G., Clara N., Antonino G., Nicola T., Silverio T., Giuseppe T., Daniele S., Aandrea M., Lucia M., Aangela V., Emanuela M., Alain G., Valentina M., Enrico C., Loretta D., Alessandra C., Marina C., Luca M., Agnese F., Angelo Fedele S., Domenico C., Luisa C., Emilio B., Nicla L.V., Carlo G., Pia D.S., Rossana M., Enzo V., Ida P., Francesco G., Vito L., Elisa L., Corrado F., Mario R., Vincenzo A., Giuseppina R., Antonio R., Maria Rosaria V., Rossana B., Mirco P., Katia C., Claudio Z., Ornella G., Editta B., Lorenzo L., Icro M., Pietro D.M., Daniele G., Ruggero D.M., Emanuela R., Gennaro C., Alice V., Isabella S., Marco M., Maddalena B., Antonio G., and Patrizia V.
- Subjects
0301 basic medicine ,Oncology ,Physiology ,Receptor, ErbB-2 ,Clinical Biochemistry ,Ado-Trastuzumab Emtansine ,Settore MED/06 ,body mass index ,HER2-positive metastatic breast cancer ,pertuzumab ,trastuzumab emtansine ,chemistry.chemical_compound ,0302 clinical medicine ,Antineoplastic Agents, Immunological ,Aged, 80 and over ,education.field_of_study ,Univariate analysis ,Middle Aged ,Metastatic breast cancer ,Progression-Free Survival ,Quartile ,030220 oncology & carcinogenesis ,Disease Progression ,Female ,Pertuzumab ,medicine.drug ,Adult ,medicine.medical_specialty ,Population ,Breast Neoplasms ,Antibodies, Monoclonal, Humanized ,03 medical and health sciences ,Breast cancer ,Settore MED/04 - PATOLOGIA GENERALE ,Internal medicine ,medicine ,Humans ,Obesity ,education ,Aged ,business.industry ,nutritional and metabolic diseases ,Cell Biology ,Overweight ,medicine.disease ,030104 developmental biology ,chemistry ,Trastuzumab emtansine ,MED/06 - ONCOLOGIA MEDICA ,business ,Body mass index - Abstract
Body mass index (BMI) is a main indicator of obesity and its association with breast cancer is well established. However, little is known in the metastatic setting, especially in HER2-positive patients. We assessed the influence of BMI on clinical outcomes of patients treated with pertuzumab and/or trastuzumab emtansine (T-DM1) for HER2+ metastatic breast cancer (mBC). BMI was addressed as a categorical variable, being classified on the basis of the following ranges, that is, 18.5-24.9, 25-29.9, and 30.0-34.9, namely, normal weight, overweight, and Class I obesity. The outcomes chosen were progression-free survival to first-line chemotherapy (PFS1) and overall survival (OS). Overall (N = 709), no impact of BMI was observed on PFS1 (p = .15), while BMI ≥ 30 was associated with worse OS (p = .003). In subjects who progressed to first line (N = 575), analyzing data across PFS1 quartiles and strata of disease burden, BMI predicted lower PFS1 in patients within the I PFS1 quartile and with the lowest disease burden (p = .001). Univariate analysis showed a detrimental effect of BMI ≥ 30 on OS for women within the I PFS1 quartile (p = .03). Results were confirmed in multivariate analysis. According to PFS1 quartiles a higher percentage of patients with high BMI and low disease burden progressed within 6 months of therapy. The effect of BMI on prognosis was also confirmed in multivariate analysis of OS for overall population. In our cohort, a BMI ≥ 30 correlated with worse OS in patients with HER2+ mBC who received pertuzumab and/or T-DM1 but had no impact on PFS to first line. BMI predicted worse I PFS1 quartile.
- Published
- 2020
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.